Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose

Goldberg, 2008, Effects of niacin on glucose control in patients with dyslipidemia, Mayo Clin Proc, 83, 470, 10.4065/83.4.470 Guyton, 2007, Safety considerations with niacin therapy, Am J Cardiol, 99, 22C, 10.1016/j.amjcard.2006.11.018 Linke, 2009, Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance, Atherosclerosis, 205, 207, 10.1016/j.atherosclerosis.2008.11.026 Vittone, 2007, Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS), J Clin Lipidol, 1, 203, 10.1016/j.jacl.2007.05.003 Chang, 2006, Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance, J Clin Endocrinol Metab, 91, 3303, 10.1210/jc.2006-0913 Capuzzi, 1998, Efficacy and safety of an extended-release niacin (Niaspan): a long-term study, Am J Cardiol, 82, 74U, 10.1016/S0002-9149(98)00731-0 Van, 2002, Comparison of extended release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus, Am J Cardiol, 89, 1306, 10.1016/S0002-9149(02)02333-0 Grundy, 2002, Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial, Arch Intern Med, 162, 1568, 10.1001/archinte.162.14.1568 Elam, 2000, Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial, JAMA, 284, 1263, 10.1001/jama.284.10.1263 Santaguida, 2005, Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose, Evid Rep Technol Assess (Summ), 128, 1 Gerstein, 1999, Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study, J Am Coll Cardiol, 33, 612, 10.1016/S0735-1097(98)00637-8 Anand, 2012, Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study, Eur J Prev Cardiol, 19, 755, 10.1177/1741826711409327 Cashin-Hemphill, 1990, Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up, JAMA, 264, 3013, 10.1001/jama.1990.03450230049028 Blankenhorn, 1987, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts, JAMA, 257, 3233, 10.1001/jama.1987.03390230069027 Beysen, 2012, Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study, Diabetologia, 55, 432, 10.1007/s00125-011-2382-3 Zieve, 2007, Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes, Clin Ther, 29, 74, 10.1016/j.clinthera.2007.01.003 Fonseca, 2008, Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy, Diabetes Care, 31, 1479, 10.2337/dc08-0283 Goldberg, 2008, Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy, Arch Intern Med, 168, 1531, 10.1001/archinte.168.14.1531 Marina, 2012, Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function, Diabetes Care, 35, 1119, 10.2337/dc11-2050 Marrs, 2012, Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl, Drugs Aging, 29, e1, 10.2165/11599290-000000000-00000 Jones, 2009, Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes, Curr Med Res Opin, 25, 2239, 10.1185/03007990903126791 Davidson, 2008, Interrupting bile-acid handling and lipid and glucose control: effects of colesevelam on glucose levels, J Clin Lipidol, 2, S29, 10.1016/j.jacl.2008.01.009 Davidson, 2010, A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia, Am J Cardiovasc Drugs, 10, 305, 10.2165/11584310-000000000-00000 Wojczynski, 2011, High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study, Lipids Health Dis, 10, 181, 10.1186/1476-511X-10-181 Garvey, 2003, Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance, Diabetes, 52, 453, 10.2337/diabetes.52.2.453 Arsenault, 2009, HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study, Atherosclerosis, 206, 276, 10.1016/j.atherosclerosis.2009.01.044 Goff, 2005, Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study, Metabolism, 54, 264, 10.1016/j.metabol.2004.09.002 Mora, 2010, Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women, Diabetes, 59, 1153, 10.2337/db09-1114 Matthews, 1985, Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883 Gerber, 2004, Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy, Clin Infect Dis, 39, 419, 10.1086/422144 Dubé, 2003, Clin Infect Dis, 37, 613, 10.1086/378131